2-Year Faricimab Results: 'Visual Gains With Fewer Injection

Vision improvements in diabetic macular edema with faricimab were similar to those with aflibercept, with fewer injections, at 2 years. This follows recent FDA approval based on 1-year trial results.

Related Keywords

Florida , United States , Deerfield Beach , American , Charlesj Danzig , Genentech Roche , Swarup Das , Regeneron Pharmaceuticals , University Of New Mexico School Medicine , Genentech , Drug Administration , American Diabetes Association , Rand Eye Institute , Novartis , Scientific Sessions , Medscape Medical News , Medscape Medical , New Mexico School , Diabetic Retinopathy , Diabetic Macular Edema , Microvascular Complications Of Diabetes , Exudative Age Related Macular Degeneration , Xudative Armd , Macular Degeneration , Ge Related Macular Degeneration Armd , Retinal Disease , Clinical Research , Clinical Trials , Linical Studies , Vegf Vascular Endothelial Growth Factor , Vascular Endothelial Growth Factor , Ascular Endothelial Growth Factor Vegf , Diabe ,